对于免疫疗法不耐药/不符合条件的皮肤状细胞癌的 cetuximab
Julian A Marin-Acevedo1, Bethany M Withycombe2, Youngchul Kim3
1Medical Oncology, Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Indianapolis, IN 46202, USA.
Cancers
|June 28, 2023
概括
塞图西马布在晚期皮肤状细胞癌 (CSCC) 患者中显示出有效性,这些患者对免疫检查点抑制剂 (ICI) 具有抗性或不合格. 在ICI失败后立即使用产生了快速,持久的反应,这表明它是首选治疗方法.
科学领域:
- 在瘤学瘤学.
- 皮肤病学 皮肤病学
- 免疫治疗是一种免疫疗法.
背景情况:
- 在免疫检查点抑制剂 (ICI) 失败后,晚期皮肤状细胞癌 (CSCC) 的治疗选择有限.
- 在ICI耐药或不合格的CSCC患者中,塞图西马布的疗效需要进一步研究.
研究的目的:
- 评估塞图西马布在局部发达或转移性CSCC的患者中的有效性.
- 根据先前ICI治疗相对于 cetuximab 给药时间的结果进行比较.
主要方法:
- 对23名患有晚期CSCC的患者进行了回顾性分析,分为三个队列:即时ICI失败,非即时ICI失败和没有先前ICI.
- 主要终点:整体反应率 (ORR). 二级终点:疾病控制率 (DCR),无进展生存率 (PFS),总生存率 (OS),反应时间 (TTR) 和毒性.
主要成果:
- 塞图西马布显示高ORR (64%在直接ICI失败队列中,80%在没有先前ICI队列中) 和DCR (分别为91%和80%).
- 在ICI失败后立即接受塞图西马布的患者经历了快速 (TTR 2.0个月) 和持久的反应,PFS的中位数为17.3个月.
- 在所有治疗组中,塞图西马布的耐受性很好.
结论:
- 塞图西马布是晚期CSCC患者的有效治疗选择,患者有ICI衰竭或禁忌.
- 在ICI失败后立即给予塞图西马布可能会提供特别快速和持久的反应,可能将其确立为首选的后续治疗.
更多相关视频
04:04Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
Published on: February 12, 2017
10.5K
09:34Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography
Published on: February 17, 2022
3.4K
相关概念视频
Tumor Immunotherapy
575
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
575
Targeted Cancer Therapies
7.7K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.7K
Skin Cancer
4.2K
Skin cancer is a type of cancer that occurs when there is an abnormal growth of skin cells, usually triggered by damage to the DNA within the skin cells. It is primarily caused by exposure to ultraviolet (UV) radiation from the sun or artificial sources like tanning beds. Skin cancer is the most common type of cancer worldwide, and its incidence continues to rise.
Basal Cell Carcinoma (BCC): BCC is the most common type of skin cancer, accounting for about 80% of cases. It typically develops in...
Basal Cell Carcinoma (BCC): BCC is the most common type of skin cancer, accounting for about 80% of cases. It typically develops in...
4.2K
Treatment Resistant Cancers
3.4K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K
